Britain's biggest pharmaceuticals giant GlaxoSmithKline today set up a joint venture with Shenzhen Neptunus to develop influenza vaccines for China.
Glaxo is paying £21 million for a 40% stake, and Shenzhen is spending £31 million on 60% opf the business.
The agreement, which covers vaccines for seasonal and pandemic flu vaccines, helps Brentford-based Glaxo to secure its position as a leading flu-vaccine producer.
Shares of the UK’s two biggest package holiday operators were among the heaviest blue-chip fallers today after one broker decided that their outlook was far from sunny
“The board of British Airways, with fees of £50,000 a year for a part-time director attending seven meetings and all those unlimited first class flights for them and the family, has been one of the most eye-catching City gravy trains. But that train is about to get a lot shorter
Morning:
13°c
